{"url_path":"/sec/asbp/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-023802-index.html","accession_number":"0001493152-26-023802","cik":"0001847345","ticker":"ASBP","issuer_name":"Aspire Biopharma Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-023802-index.html","primary_entity_key":"0001847345","primary_entity_name":"Aspire Biopharma Holdings, Inc."},"word_count":39,"has_tables":true,"body_markdown":"**ITEM\n5. OTHER INFORMATION**\n\n \n\nDuring the quarter ended March 31, 2026, none of our\ndirectors or officers adopted, modified or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements as\ndefined in Item 408 of Regulation S-K."}